KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short-term Investments (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Short-term Investments for 17 consecutive years, with $248.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments rose 27.75% year-over-year to $248.9 million, compared with a TTM value of $248.9 million through Dec 2025, up 27.75%, and an annual FY2025 reading of $248.9 million, up 27.75% over the prior year.
  • Short-term Investments was $248.9 million for Q4 2025 at Biomarin Pharmaceutical, up from $227.7 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $572.0 million in Q1 2023 and bottomed at $194.9 million in Q4 2024.
  • Average Short-term Investments over 5 years is $371.9 million, with a median of $380.3 million recorded in 2021.
  • The sharpest move saw Short-term Investments soared 32.91% in 2022, then plummeted 47.63% in 2024.
  • Year by year, Short-term Investments stood at $426.6 million in 2021, then skyrocketed by 32.91% to $567.0 million in 2022, then crashed by 43.8% to $318.7 million in 2023, then tumbled by 38.85% to $194.9 million in 2024, then increased by 27.75% to $248.9 million in 2025.
  • Business Quant data shows Short-term Investments for BMRN at $248.9 million in Q4 2025, $227.7 million in Q3 2025, and $218.3 million in Q2 2025.